Officer and Director Transaction Report

Christopher Ryan Sullivan, Chief Financial Officer of Avalo Therapeutics, Inc., reported a transaction on June 10, 2026. He disposed of 138 shares of common stock at a price of $13.10 per share. Following this transaction, Mr. Sullivan owns 40,773 shares. The filing also notes that 588 shares were acquired under the Issuer's Employee Stock Purchase Plan as part of this reporting transaction. The report was signed on June 12, 2026.